Morgan Stanley Unity Biotechnology, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.4 - $4.27 $13,879 - $148,164	34,699 Added 23.54%	182,084 $72,000
Q2 2022 Oct 27, 2022	BUY	$0.56 - $1.29 $1,817 - $4,187	3,246 Added 2.25%	147,385 $82,000
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.29 $1,817 - $4,187	3,246 Added 2.25%	147,385 $82,000
Q1 2022 Oct 27, 2022	SELL	$0.72 - $1.86 $2,337 - $6,037	-3,246 Reduced 2.2%	144,139 $161,000
Q1 2022 May 13, 2022	SELL	$0.72 - $1.86 $21,004 - $54,261	-29,173 Reduced 16.83%	144,139 $161,000
Q4 2021 Feb 14, 2022	SELL	$1.3 - $3.17 $424,040 - $1.03 Million	-326,185 Reduced 65.3%	173,312 $253,000
Q3 2021 Nov 15, 2021	BUY	$2.91 - $4.5 $1.45 Million - $2.25 Million	499,497 New	499,497 $1.5 Million

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $20.6M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.